{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:42:09Z","timestamp":1790721729573,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115552","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:10:21Z","timestamp":1758143421000},"page":"115552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nanobody therapeutics in autoimmune and immune-mediated inflammatory diseases: experimental insights and translational strategies"],"prefix":"10.1016","volume":"166","author":[{"given":"Rana Sherbaevna","family":"Salieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2025.115552_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115552_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70262","article-title":"Autoimmune diseases: molecular pathogenesis and therapeutic targets","volume":"6","author":"Song","year":"2025","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41401-023-01207-2","article-title":"Autoimmune diseases: targets, biology, and drug discovery","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0020","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.3390\/ijms24044176","article-title":"Application Progress of the single domain antibody in medicine","volume":"24","author":"Tang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114726","article-title":"Nanobodies: Robust miniprotein binders in biomedicine","volume":"195","author":"Yong Joon Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0030","first-page":"11","article-title":"The therapeutic potential of Nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115552_bb0035","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician\u2019s perspective","volume":"43","author":"Katarzyna","year":"2023","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2025.115552_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115162","article-title":"Toward immune tolerance in rheumatoid arthritis: emerging immunotherapies and targets for long-term remission","volume":"162","author":"Afshari","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115552_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14712598.2023.2231344","article-title":"Ozoralizumab: first Nanobody\u00ae therapeutic for rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0050","first-page":"501","article-title":"Nanobody-as versatile tool emerging in autoimmune diseases","volume":"5","author":"Wang","year":"2024","journal-title":"Smart Mater. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0055","doi-asserted-by":"crossref","first-page":"18102","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115552_bb0060","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68253","article-title":"A general approach for stabilizing nanobodies for intracellular expression","volume":"11","author":"Dingus","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.intimp.2025.115552_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer","volume":"8","author":"Van Audenhove","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2025.115552_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107086","article-title":"Biologics, theranostics, and personalized medicine in drug delivery systems","volume":"201","author":"Puccetti","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.115552_bb0075","series-title":"Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine. In: Gautam V, Kumar R, Das Manandhar K, Kamble SC, editors. Nanomedicine. Cham: Springer Nature Switzerland","author":"Singh","year":"2024"},{"key":"10.1016\/j.intimp.2025.115552_bb0080","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/DDDT.S134470","article-title":"Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Elverdi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.115552_bb0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.54097\/hset.v36i.5646","article-title":"The treatments of Carvykti in multiple myeloma","volume":"36","author":"He","year":"2023","journal-title":"Highlights Sci. Eng. Technol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115552_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/13543784.2023.2249814","article-title":"Current status and future expectations of nanobodies in oncology trials","volume":"32","author":"De Pauw","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun. Signal. CCS"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12032-024-02588-y","article-title":"Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy","volume":"42","author":"Hosseininejad-Chafi","year":"2024","journal-title":"Med. Oncol. Northwood Lond., Engl."},{"key":"10.1016\/j.intimp.2025.115552_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-2075-5_1","article-title":"Nanobodies: from serendipitous discovery of heavy chain-only antibodies in camelids to a wide range of useful applications","volume":"2446","author":"Ji","year":"2022","journal-title":"Methods Mol, Biol, Clifton, NJ"},{"key":"10.1016\/j.intimp.2025.115552_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5604\/17322693.1000334","article-title":"Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine?","volume":"66","author":"Smolarek","year":"2012","journal-title":"Postepy Hig. Med. Doswiadczalnej Online"},{"key":"10.1016\/j.intimp.2025.115552_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115239","article-title":"Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release","volume":"207","author":"Liu","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: from discovery to AI-driven design","volume":"14","author":"Zhu","year":"2025","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-025-02270-5","article-title":"Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines","volume":"24","author":"Maksymova","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0135","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2025.115552_bb0140","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2017.01589","article-title":"Camelid single-domain antibodies: historical perspective and future outlook","volume":"8","author":"Arbabi-Ghahroudi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of Nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0150","doi-asserted-by":"crossref","DOI":"10.1042\/BST20241419","article-title":"Advances in nanobody multimerization and multispecificity: from in vivo assembly to in vitro production","volume":"53","author":"Al-Seragi","year":"2025","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.intimp.2025.115552_bb0155","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0160","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","article-title":"The structural basis of nanobody unfolding reversibility and thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-021-00750-5","article-title":"Nanobody: a promising toolkit for molecular imaging and disease therapy","volume":"11","author":"Bao","year":"2021","journal-title":"EJNMMI Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.115552_bb0170","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-engineering for modulated effector functions-improving antibodies for Cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies Basel Switz."},{"issue":"9","key":"10.1016\/j.intimp.2025.115552_bb0180","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/anie.201708459","article-title":"Nanobodies: chemical functionalization strategies and intracellular applications","volume":"57","author":"Schumacher","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"6","key":"10.1016\/j.intimp.2025.115552_bb0185","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0190","article-title":"Interleukin in immune-mediated diseases: an updated review","author":"Zaroon","year":"2024","journal-title":"Mol. Biotechnol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115552_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100865","article-title":"Nanobodies: from high-throughput identification to therapeutic development","volume":"23","author":"Fridy","year":"2024","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140057","article-title":"Development and therapeutic assessment of bispecific nanobodies targeting B-cell activating factor and interleukin-17 for the neutralization of inflammatory mediators in autoimmune diseases","volume":"305","author":"Xin","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2025.115552_bb0210","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and Nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155627","article-title":"Immunogenicity of monoclonal antibody: causes, consequences, and control strategies","volume":"263","author":"Asmani","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.intimp.2025.115552_bb0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0225","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.pharep.2014.05.004","article-title":"TNF inhibitors \u2013 mechanisms of action, approved and off-label indications","volume":"66","author":"Cessak","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0230","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.115552_bb0235","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2025.115552_bb0240","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2544689","article-title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems","volume":"32","author":"Lin","year":"2025","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0250","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41598-018-23277-7","article-title":"Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease","volume":"8","author":"Crowe","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0255","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03639045.2018.1542708","article-title":"Oral delivery of the anti-tumor necrosis factor \u03b1 domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys","volume":"45","author":"Crowe","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50545-x","article-title":"Oral anti-tumour necrosis factor domain antibody V565 provides high intestinal concentrations, and reduces markers of inflammation in ulcerative colitis patients","volume":"9","author":"Nurbhai","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-022-01821-0","article-title":"Ozoralizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"10284","key":"10.1016\/j.intimp.2025.115552_bb0270","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet Lond., Engl."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0275","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13543784.2025.2500292","article-title":"Assessing the clinical progress of the bispecific nanobody sonelokimab","volume":"34","author":"Dogra","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.intimp.2025.115552_bb0280","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/pharmaceutics12100937","article-title":"Brain delivery of single-domain antibodies: a focus on VHH and VNAR","volume":"12","author":"Pothin","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12987-022-00374-4","article-title":"VHHs as tools for therapeutic protein delivery to the central nervous system","volume":"19","author":"Wouters","year":"2022","journal-title":"Fluids Barriers CNS"},{"issue":"17","key":"10.1016\/j.intimp.2025.115552_bb0290","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2025.115552_bb0295","doi-asserted-by":"crossref","unstructured":"Pati\u00f1o-Martinez E, Kaplan MJ. Immunometabolism in systemic lupus erythematosus. Nat. Rev. Rheumatol.;21(7):377\u201395. https:\/\/www.nature.com\/articles\/s41584-025-01267-0.","DOI":"10.1038\/s41584-025-01267-0"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s11658-025-00749-z","article-title":"Immune cell aberrations in systemic lupus erythematosus: navigating the targeted therapies toward precision management","volume":"30","author":"Wu","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.intimp.2025.115552_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114738","article-title":"Novel diagnostic biomarker and immune profiling of GPR56+ B cell subsets in systemic lupus erythematosus","volume":"157","author":"Xiong","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115552_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103648","article-title":"Immunopathogenesis of systemic lupus erythematosus: an update","volume":"23","author":"Arnaud","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2025.115552_bb0315","article-title":"B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2025.115552_bb0320","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood.2022016243","article-title":"A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105627","article-title":"Type 1 interferons: a target for immune-mediated inflammatory diseases (IMIDs)","volume":"91","author":"Mathian","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2025.115552_bb0330","article-title":"Interferon receptor trafficking and signaling: journey to the cross roads","volume":"11","author":"Zanin","year":"2020","journal-title":"Front. Immunol."},{"issue":"710","key":"10.1016\/j.intimp.2025.115552_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abe4627","article-title":"IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs","volume":"14","author":"Shemesh","year":"2021","journal-title":"Sci. Signal."},{"issue":"23","key":"10.1016\/j.intimp.2025.115552_bb0340","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115552_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1243651","article-title":"Nanoparticles and cytokine response","volume":"11","author":"Nasrullah","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3892\/ijmm.2023.5336","article-title":"Nanobodies in cytokine-mediated immunotherapy and immunoimaging (review)","volume":"53","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0360","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0365","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0375","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115552_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102490","article-title":"Are lupus animal models useful for understanding and developing new therapies for human SLE?","volume":"112","author":"Moore","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0385","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2341443","article-title":"Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions","volume":"16","author":"Mullin","year":"2024","journal-title":"mAbs"},{"issue":"7","key":"10.1016\/j.intimp.2025.115552_bb0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00109-012-0866-3","article-title":"Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus","volume":"90","author":"Ouyang","year":"2012","journal-title":"J. Mol. Med. Berl. Ger."},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0395","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2012.03.005","article-title":"Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha","volume":"143","author":"Lichtman","year":"2012","journal-title":"Clin. Immunol. Orlando, Fla."},{"issue":"681","key":"10.1016\/j.intimp.2025.115552_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115552_bb0405","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","article-title":"Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis","volume":"54","author":"Coppieters","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2025.115552_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a humanized anti-TNF\u03b1 NANOBODY\u00ae compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of Administration of an Anti-TNF\u03b1 IgG","volume":"13","author":"Ishiwatari-Ogata","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115552_bb0415","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115552_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105343","article-title":"Bispecific soluble cytokine receptor-nanobody fusions inhibit interleukin (IL-)6 trans-signaling and IL-12\/23 or tumor necrosis factor (TNF) signaling","volume":"299","author":"Gesiorowski","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0425","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.kint.2021.11.014","article-title":"Prediction models of treatment response in lupus nephritis","volume":"101","author":"Ayoub","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2025.115552_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105785","article-title":"Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted therapies","volume":"117","author":"Shang","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2025.115552_bb0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8802-0_1","article-title":"Collagen-induced arthritis models","volume":"1868","author":"Miyoshi","year":"2018","journal-title":"Methods Mol, Biol, Clifton, NJ"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12967-024-05105-x","article-title":"Extracorporeal photopheresis reduces inflammation and joint damage in a rheumatoid arthritis murine model","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115552_bb0445","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2016.00213","article-title":"K\/BxN serum-transfer arthritis as a model for human inflammatory arthritis","volume":"7","author":"Christensen","year":"2016","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0450","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00281-003-0125-3","article-title":"The TNF-alpha transgenic mouse model of inflammatory arthritis","volume":"25","author":"Li","year":"2003","journal-title":"Springer Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41419-018-1246-x","article-title":"Transgenic mice overexpressing human TNF-\u03b1 experience early onset spontaneous intervertebral disc herniation in the absence of overt degeneration","volume":"10","author":"Gorth","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0460","doi-asserted-by":"crossref","DOI":"10.1093\/discim\/kyac010","article-title":"Bench to bedside: modelling inflammatory arthritis","volume":"2","author":"Chidomere","year":"2023","journal-title":"Discov. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0465","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2498164","article-title":"Development of potent humanized TNF\u03b1 inhibitory nanobodies for therapeutic applications in TNF\u03b1-mediated diseases","volume":"17","author":"Yin","year":"2025","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0470","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/mr\/roac126","article-title":"Efficacy and safety of anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab\u2019 without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115552_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1149874","article-title":"Unique structure of ozoralizumab, a trivalent anti-TNF\u03b1 NANOBODY\u00ae compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation","volume":"14","author":"Kyuuma","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0480","first-page":"341","article-title":"Next-generation anti-TNF\u03b1 agents: the example of Ozoralizumab","volume":"38","author":"Tsumoto","year":"2024","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.intimp.2025.115552_bb0485","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Rodr\u00edguez Mur\u00faa","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2025.115552_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.711362","article-title":"The efficacy of mesenchymal stem cell therapies in rodent models of multiple sclerosis: an updated systematic review and Meta-analysis","volume":"12","author":"He","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0495","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115552_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115200","article-title":"Autoimmune encephalitis with CASPR2 antibody: a case series and updated literature review","volume":"162","author":"Wu","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115552_bb0505","doi-asserted-by":"crossref","first-page":"7169","DOI":"10.4049\/jimmunol.0901906","article-title":"Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes","volume":"183","author":"J\u00e4ger","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0510","first-page":"477","article-title":"Molecular mechanisms involved in T cell migration across the blood-brain barrier","volume":"113","author":"Engelhardt","year":"2006","journal-title":"J. Neural Transm. Vienna Austria 1996"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0515","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/s41598-018-22872-y","article-title":"Diversity of innate immune cell subsets across spatial and temporal scales in an EAE mouse model","volume":"8","author":"Caravagna","year":"2018","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.intimp.2025.115552_bb0520","doi-asserted-by":"crossref","first-page":"13081","DOI":"10.3390\/ijms232113081","article-title":"CNS Pericytes modulate local T cell infiltration in EAE","volume":"23","author":"Koch","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0525","article-title":"Effect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis","volume":"71","author":"Pyka-Fosciak","year":"2020","journal-title":"J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc."},{"key":"10.1016\/j.intimp.2025.115552_bb0530","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fchem.2019.00489","article-title":"Novel ligands targeting \u03b14\u03b21 integrin: therapeutic applications and perspectives","volume":"7","author":"Baiula","year":"2019","journal-title":"Front. Chem."},{"issue":"10","key":"10.1016\/j.intimp.2025.115552_bb0535","first-page":"5909","article-title":"Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis","volume":"182","author":"Coisne","year":"2009","journal-title":"J. Immunol. Baltim, Md 1950"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0540","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191123","article-title":"Targeting interleukin-17 in chronic inflammatory disease: a clinical perspective","volume":"217","author":"Zwicky","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115552_bb0545","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","article-title":"The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment","volume":"122","author":"Robinson","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115552_bb0550","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0555","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primer"},{"key":"10.1016\/j.intimp.2025.115552_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115153","article-title":"FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model","volume":"162","author":"Shi","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115552_bb0565","first-page":"1637","article-title":"FcRn inhibitors: a novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0570","first-page":"183","article-title":"Neonatal fc receptor (FcRn)-a novel therapeutic approach for autoimmune disease","volume":"76","author":"Murai","year":"2024","journal-title":"Brain Nerve Shinkei Kenkyu No Shinpo"},{"key":"10.1016\/j.intimp.2025.115552_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1526317","article-title":"The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?","volume":"16","author":"Michailidou","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0580","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune system","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115238","article-title":"Addressing bias in biomarker discovery for inflammatory bowel diseases: a multi-faceted analytical approach","volume":"163","author":"Takefuji","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0590","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12916-024-03690-8","article-title":"Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review","volume":"22","author":"Jeffers","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2025.115552_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116303","article-title":"Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives","volume":"225","author":"Singh","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115552_bb0600","article-title":"Research progress and applications of multivalent, multispecific and modified nanobodies for disease treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"52","key":"10.1016\/j.intimp.2025.115552_bb0605","article-title":"Programmable circular multivalent Nanobody-targeting chimeras (mNbTACs) for multireceptor-mediated protein degradation and targeted drug delivery","volume":"63","author":"Jiang","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0610","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/antib8010013","article-title":"Nanobody engineering: toward next generation immunotherapies and Immunoimaging of Cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies Basel Switz."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0615","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12951-025-03169-5","article-title":"Unveiling the new chapter in nanobody engineering: advances in traditional construction and AI-driven optimization","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0620","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0625","unstructured":"A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn*s disease."},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70168","article-title":"Gut microbiota Dysbiosis: pathogenesis, diseases, prevention, and therapy","volume":"6","author":"Shen","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0635","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5056\/jnm20149","article-title":"Gut microbial Dysbiosis in the pathogenesis of gastrointestinal Dysmotility and metabolic disorders","volume":"27","author":"Singh","year":"2021","journal-title":"J, Neurogastroenterol, Motil."},{"key":"10.1016\/j.intimp.2025.115552_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2021.100928","article-title":"The importance of Faecalibacterium prausnitzii in human health and diseases","volume":"43","author":"Parsaei","year":"2021","journal-title":"New Microbes New Infect."},{"key":"10.1016\/j.intimp.2025.115552_bb0645","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1196\/annals.1443.021","article-title":"Regulation and function of proinflammatory TH17 cells","volume":"1143","author":"Martinez","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2025.115552_bb0650","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3389\/fimmu.2017.01073","article-title":"VHH-based bispecific antibodies targeting cytokine production","volume":"8","author":"Nosenko","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0655","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.actbio.2020.09.017","article-title":"Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis","volume":"116","author":"Naeem","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.intimp.2025.115552_bb0660","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jconrel.2025.02.043","article-title":"Long-acting injectable nanoparticle formulation for sustained release of anti-TNF-\u03b1 antibody therapeutic in ulcerative colitis treatment","volume":"380","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0665","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12951-021-01090-1","article-title":"How could nanobiotechnology improve treatment outcomes of anti-TNF-\u03b1 therapy in inflammatory bowel disease? Current knowledge, future directions","volume":"19","author":"Eder","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2025.115552_bb0670","series-title":"Methods in Microbiology","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0580-9517(02)31030-4","article-title":"29 combining gnotobiotic mouse models with functional genomics to define the impact of the microflora on host physiology","author":"Hooper","year":"2002"},{"issue":"4","key":"10.1016\/j.intimp.2025.115552_bb0675","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/genes13040706","article-title":"Pathogenesis of type 1 diabetes: established facts and new insights","volume":"13","author":"Zajec","year":"2022","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101936","article-title":"B cell activation and autoantibody production in autoimmune diseases","volume":"38","author":"Sun","year":"2024","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2025.115552_bb0685","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-0716-0385-7_6","article-title":"Mouse models of autoimmune diabetes: the nonobese diabetic (NOD) mouse","volume":"2128","author":"Chen","year":"2020","journal-title":"Methods Mol, Biol, Clifton, NJ"},{"key":"10.1016\/j.intimp.2025.115552_bb0690","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaut.2015.08.019","article-title":"The importance of the non obese diabetic (NOD) mouse model in autoimmune diabetes","volume":"66","author":"Pearson","year":"2016","journal-title":"J. Autoimmun."},{"issue":"7","key":"10.1016\/j.intimp.2025.115552_bb0695","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41590-023-01503-3","article-title":"Conserved stromal\u2013immune cell circuits secure B cell homeostasis and function","volume":"24","author":"L\u00fctge","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115552_bb0700","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0065-2776(08)60490-3","article-title":"The murine autoimmune diabetes model: NOD and Related strains","author":"Kikutani","year":"1992"},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0705","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrendo.2014.236","article-title":"Thinking bedside at the bench: the NOD mouse model of T1DM","volume":"11","author":"Reed","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115552_bb0710","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401355","article-title":"Oral delivery strategies for biological drugs","volume":"9","author":"Zeng","year":"2025","journal-title":"Small Methods"},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0715","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115552_bb0720","unstructured":"ALX-0061-1.1 10 - CSR synopsis - for results disclosure - final."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0725","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005710","article-title":"Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II\/III OHZORA trial","volume":"11","author":"Miyazaki","year":"2025","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0730","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2025.115552_bb0735","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood-2021-148839","article-title":"Long-term safety and efficacy of Caplacizumab for acquired thrombotic thrombocytopenic Purpura (aTTP): the post-HERCULES study","volume":"138","author":"Scully","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2025.115552_bb0740","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/jth.15892","article-title":"Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study","volume":"20","author":"Scully","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296737","article-title":"AbImmPred: an immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features. Usmani SS, editor","volume":"19","author":"Wang","year":"2024","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0750","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s42256-023-00778-3","article-title":"Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV","volume":"6","author":"Ramon","year":"2024","journal-title":"Nat. Mach. Intell."},{"issue":"9","key":"10.1016\/j.intimp.2025.115552_bb0755","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3390\/ijms23095009","article-title":"Camelid single-domain antibodies: promises and challenges as lifesaving treatments","volume":"23","author":"Arbabi-Ghahroudi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.intimp.2025.115552_bb0760","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1177\/1535370219881129","article-title":"Structure and development of single domain antibodies as modules for therapeutics and diagnostics","volume":"244","author":"Hoey","year":"2019","journal-title":"Exp. Biol. Med. Maywood, NJ"},{"issue":"12","key":"10.1016\/j.intimp.2025.115552_bb0765","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/pro.734","article-title":"Affinity transfer to a human protein by CDR3 grafting of camelid VHH","volume":"20","author":"Inoue","year":"2011","journal-title":"Protein Sci. Publ. Protein Soc."},{"issue":"6","key":"10.1016\/j.intimp.2025.115552_bb0770","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4161\/mabs.36389","article-title":"A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells","volume":"6","author":"Choi","year":"2014","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.intimp.2025.115552_bb0775","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/1873-3468.15064","article-title":"Thermodynamic versus kinetic basis for the high conformational stability of nanobodies for therapeutic applications","volume":"599","author":"G\u00f3mez-Mulas","year":"2025","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0780","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-019-1094-0","article-title":"Screening and purification of nanobodies from E. Coli culture supernatants using the hemolysin secretion system","volume":"18","author":"Ruano-Gallego","year":"2019","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.intimp.2025.115552_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2020.105607","article-title":"Nanobody production can be simplified by direct secretion from Escherichia coli","volume":"170","author":"Iwaki","year":"2020","journal-title":"Protein Expr. Purif."},{"issue":"3","key":"10.1016\/j.intimp.2025.115552_bb0790","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies Basel Switz."},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0795","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.intimp.2025.115552_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended Nanobody-based CD38-specific bispecific Killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front. Immunol."},{"issue":"33","key":"10.1016\/j.intimp.2025.115552_bb0805","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua WF, Kiener PA, Wu H.","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2025.115552_bb0810","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.intimp.2025.115552_bb0815","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.intimp.2025.115552_bb0820","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2025.115552_bb0825","series-title":"A Study of ALXN1720 (NCT04522166)","author":"ClinicalTrials.gov","year":"2023"},{"key":"10.1016\/j.intimp.2025.115552_bb0830","series-title":"Immunobiology: The Immune System in Health and Disease","article-title":"The structure of a typical antibody molecule","author":"Janeway","year":"2001"},{"key":"10.1016\/j.intimp.2025.115552_bb0835","unstructured":"ALX-0061 Seamless \"First-in-Human\" Phase I\/II POC Study in Patients with Active RA on Stable MTX Treatment, Ann. Rheum. Dis. 72 (2013) A375.2, Abstract No. 1307."},{"key":"10.1016\/j.intimp.2025.115552_bb0840","unstructured":"Ablynx, An open-label extension study assessing the long-term efficacy and safety of ALX-0061 in subjects with rheumatoid arthritis, Clinical trial registration NCT02518620, US Clinical Trials Registry, 2019, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02518620."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:51:28Z","timestamp":1763697088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925015437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":168,"alternative-id":["S1567576925015437"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115552","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody therapeutics in autoimmune and immune-mediated inflammatory diseases: experimental insights and translational strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115552"}}